Rapamycin (Sirolimus) vs Vitamin D3

Mechanism

Rapamycin binds the intracellular protein FKBP12, and the rapamycin-FKBP12 complex inhibits mechanistic target of rapamycin complex 1 (mTORC1), a serine/threonine kinase that integrates nutrient sensing, growth factor signaling, and cellular energy status. mTORC1 inhibition suppresses S6K1-mediated ribosomal protein synthesis, activates ULK1-mediated autophagy and mitophagy, enhances lysosomal biogenesis via TFEB nuclear translocation, reduces senescent cell accumulation, and suppresses the SASP (senescence-associated secretory phenotype). At higher chronic doses, rapamycin also inhibits mTORC2, which regulates Akt-mediated insulin signaling — this is believed to drive the metabolic side effects.

Standard Dosing

Research indicates 5-6 mg once weekly (intermittent/pulsed dosing) for longevity protocols. This weekly pulsed approach preferentially inhibits mTORC1 while allowing mTORC2 to remain functional.

Timing

Once weekly, consistent day each week. Take with or without food (food increases bioavailability by ~35% — be consistent either way). Grapefruit juice significantly increases rapamycin bioavailability via CYP3A4 inhibition — some practitioners use this intentionally to reduce pill burden.

Cycle Duration

Long-term (years) for longevity applications. The PEARL trial assessed up to 12 months of treatment in healthy older adults.

Side Effects

• Mouth ulcers/canker sores (most common, dose-dependent)
• Elevated lipids (triglycerides and LDL — typically manageable with weekly dosing)
• Impaired wound healing
• Mild immunosuppression (increased susceptibility to infections)
• Insulin resistance (primarily from mTORC2 inhibition at higher/daily doses)
• Acne-like skin eruptions
• Thrombocytopenia and leukopenia (rare at longevity doses)

Contraindications

• Active infections (immunosuppression risk)
• Poorly healing wounds or planned surgery (delays wound healing)
• Severe hepatic impairment
• Uncontrolled hyperlipidemia
• Pregnancy and breastfeeding
• Organ transplant patients on calcineurin inhibitors (specialized dosing required)
• Active infection
• Immunocompromised states
• Poorly controlled diabetes
• Wound healing (pause 2 weeks pre-surgery)

Best Stacking Partners

Mechanism

Vitamin D3 (cholecalciferol) is hydroxylated in the liver to 25(OH)D (calcidiol), then in the kidneys to 1,25(OH)2D (calcitriol), the active hormone. Calcitriol binds the nuclear vitamin D receptor (VDR), forming a heterodimer with RXR that regulates >1000 genes. Key actions: upregulation of intestinal calcium/phosphorus absorption (TRPV6, calbindin), modulation of innate immunity (cathelicidin LL-37 antimicrobial peptide production), suppression of adaptive immune overactivation (Th1/Th17 to Treg shift), regulation of PTH and osteocalcin for bone mineralization, and modulation of insulin secretion from beta cells.

Standard Dosing

5000 IU daily (125 mcg)

Timing

With largest fat-containing meal of the day (fat-soluble). Morning preferred.

Cycle Duration

ongoing (lifelong for most people in northern latitudes)

Side Effects

• Hypercalcemia at excessive doses (>10,000 IU/day long-term without monitoring)
• Nausea/vomiting (toxicity)
• Kidney stones (with excessive calcium)
• Metallic taste (toxicity sign)

Contraindications

• Hypercalcemia
• Granulomatous diseases (sarcoidosis, some lymphomas — unregulated 1-alpha hydroxylase conversion)
• Primary hyperparathyroidism (without monitoring)
• Williams syndrome

Best Stacking Partners